A 438079P2X7 receptor antagonist,competitive and selective CAS# 899507-36-9 |
- KN-92 phosphate
Catalog No.:BCC1682
CAS No.:1135280-28-2
- KN-92 hydrochloride
Catalog No.:BCC1681
CAS No.:1431698-47-3
- A-317491
Catalog No.:BCC1320
CAS No.:475205-49-3
- Ivermectin
Catalog No.:BCC1251
CAS No.:70288-86-7
- A 438079 hydrochloride
Catalog No.:BCC1317
CAS No.:899431-18-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 899507-36-9 | SDF | Download SDF |
| PubChem ID | 11673921 | Appearance | Powder |
| Formula | C13H9Cl2N5 | M.Wt | 306.15 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : 0.2 mg/mL (0.65 mM; Need ultrasonic) | ||
| Chemical Name | 3-[[5-(2,3-dichlorophenyl)tetrazol-1-yl]methyl]pyridine | ||
| SMILES | C1=CC(=C(C(=C1)Cl)Cl)C2=NN=NN2CC3=CN=CC=C3 | ||
| Standard InChIKey | MMPAULQSJLVKHP-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C13H9Cl2N5/c14-11-5-1-4-10(12(11)15)13-17-18-19-20(13)8-9-3-2-6-16-7-9/h1-7H,8H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
A 438079 Dilution Calculator
A 438079 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2664 mL | 16.3319 mL | 32.6637 mL | 65.3275 mL | 81.6593 mL |
| 5 mM | 0.6533 mL | 3.2664 mL | 6.5327 mL | 13.0655 mL | 16.3319 mL |
| 10 mM | 0.3266 mL | 1.6332 mL | 3.2664 mL | 6.5327 mL | 8.1659 mL |
| 50 mM | 0.0653 mL | 0.3266 mL | 0.6533 mL | 1.3065 mL | 1.6332 mL |
| 100 mM | 0.0327 mL | 0.1633 mL | 0.3266 mL | 0.6533 mL | 0.8166 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
A438079 is a selective small-molecule antagonist of human P2X7 receptor with IC50 value of 300 nM [1].
The nucleotide receptor P2X7 receptor is a subtype of the P2X receptor family. It is expressed in cells of both the central nervous system and the immune system. Since the activation of P2X7 receptor by ATP is associated with the release of glutamate and cytokines, P2X7 receptor is thought to be a target of the treatment for inflammation and neurodegeneration. The tetrazole-based compound A438079 works as a competitive antagonist of P2X7 receptor and shows potent antinociceptive activity in rat model [2].
A 438079 was selective against P2X7 receptor and showed no significant activity against other P2X receptors including P2X2, P2X3 and P2X4 even at concentration up to 10 μM. For other cell-surface ion channels and receptors, A 438079 also showed no effect. In the FLIPR assay using human 1321N1 astrocytoma cells stably transfected with recombinant rat or human P2X7 receptors, pretreatment of A 438079 potently inhibited the calcium influx with IC50 values of 100 and 300 nM, respectively. In human THP-1 cells differentiated with IFNγ and LPS, A 438079 treatment inhibited interleukin-1β release stimulated by BzATP with pIC50 value of 6.7.Besides that, A 438079 was found to block the pore formation in humanTHP-1 cells [1 and 2].
In the rat model of neuropathic pain, administration of A 438079dose-dependently reduced the mechanical allodynia with ED50 value of 76 μM/kg. In mice with status epilepticus, administration of A 438079 resulted in decreased total seizure power, amplitude and reduced seizure behavior. In addition, A 438079 was found to attenuate acetaminophen-induced liver injury in mice [2, 3 and 4].
References:
[1] Donnelly-Roberts DL, Jarvis MF. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol. 2007 Jul;151(5):571-9. Epub 2007 Apr 30.
[2] Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, Grayson G, Namovic MT, Donnelly-Roberts DL, Niforatos W, Honore P, Jarvis MF, Faltynek CR, Carroll WA. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem. 2006 Jun 15;49(12):3659-66.
[3] Jimenez-Pacheco A, Mesuret G, Sanz-Rodriguez A, Tanaka K, Mooney C, Conroy R, Miras-Portugal MT, Diaz-Hernandez M, Henshall DC, Engel T. Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia. 2013 Sep;54(9):1551-61.
[4] Xie Y, Williams CD, McGill MR, Lebofsky M, Ramachandran A, Jaeschke H. Purinergic receptor antagonist A438079 protects against acetaminophen-induced liver injury by inhibiting p450 isoenzymes, not by inflammasome activation. Toxicol Sci. 2013 Jan;131(1):325-35.
- Platycoside K
Catalog No.:BCN3242
CAS No.:899447-64-4
- A 438079 hydrochloride
Catalog No.:BCC1317
CAS No.:899431-18-6
- Gymnoside III
Catalog No.:BCN8218
CAS No.:899430-03-6
- Beta-Carboline-1-propanoic acid
Catalog No.:BCN5805
CAS No.:89915-39-9
- 3-O-Acetyl-alpha-boswellic acid
Catalog No.:BCN2671
CAS No.:89913-60-0
- 3-Epichromolaenide
Catalog No.:BCN7241
CAS No.:89913-53-1
- 4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one hydrochloride
Catalog No.:BCC8647
CAS No.:898543-06-1
- XL228
Catalog No.:BCC2058
CAS No.:898280-07-4
- Esculentoside D
Catalog No.:BCN5013
CAS No.:89808-50-4
- YS-035 hydrochloride
Catalog No.:BCC6639
CAS No.:89805-39-0
- PF-3758309
Catalog No.:BCC1853
CAS No.:898044-15-0
- 5-Ethyltio-1H-Tetrazole
Catalog No.:BCC2844
CAS No.:89797-68-2
- ML 348
Catalog No.:BCC5611
CAS No.:899713-86-1
- CC-930
Catalog No.:BCC1459
CAS No.:899805-25-5
- 3-Nitro-1-(4-octylphenyl)-1-propanone
Catalog No.:BCN2250
CAS No.:899822-97-0
- 3-(Hydroxymethyl)-3-nitro-1-(4-octylphenyl)-1,4-butanediol
Catalog No.:BCN1313
CAS No.:899822-99-2
- Salicyl alcohol
Catalog No.:BCN4442
CAS No.:90-01-7
- Guaiacol
Catalog No.:BCN8311
CAS No.:90-05-1
- 1-Naphthol
Catalog No.:BCC8473
CAS No.:90-15-3
- beta-Rhamnocitrin
Catalog No.:BCN3293
CAS No.:90-19-7
- Xanthoxylin
Catalog No.:BCN4443
CAS No.:90-24-4
- 4-Methylumbelliferone
Catalog No.:BCN2563
CAS No.:90-33-5
- Xanthone
Catalog No.:BCC6493
CAS No.:90-47-1
- 3,4,5-Trimethoxycinnamic acid
Catalog No.:BCN5030
CAS No.:90-50-6
Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079.[Pubmed:23808395]
Epilepsia. 2013 Sep;54(9):1551-61.
PURPOSE: ATP is an essential transmitter/cotransmitter in neuron function and pathophysiology and has recently emerged as a potential contributor to prolonged seizures (status epilepticus) through the activation of the purinergic ionotropic P2X7 receptor (P2X7R). Increased P2X7R expression has been reported in the hippocampus, and P2X7R antagonists reduced seizure-induced damage to this brain region. However, status epilepticus also produces damage to the neocortex. The present study was designed to characterize P2X7R in the neocortex and assess effects of P2X7R antagonists on cortical injury after status epilepticus. METHODS: Status epilepticus was induced in mice by intraamygdala microinjection of kainic acid. Specific P2X7R inhibitors were administered into the ventricle before seizure induction, and cortical electroencephalography and behavior was recorded to assess seizure severity. P2X7R expression was examined in neocortex up to 24 h after status epilepticus, in epileptic mice, and in resected neocortex from patients with pharmacoresistent temporal lobe epilepsy (TLE). In addition, the induction of P2X7R after status epilepticus was investigated using transgenic P2X7R reporter mice, which express enhanced green fluorescent protein under the control of the p2x7r promoter. KEY FINDINGS: Status epilepticus resulted in increased P2X7R protein levels in the neocortex of mice. Neocortical P2X7 receptor levels were also elevated in mice that developed epilepsy after status epilepticus and in resected neocortex from patients with pharmacoresistent TLE. Immunohistochemistry determined that neurons were the major cell population transcribing the P2X7R in the neocortex within the first 8 h after status epilepticus, whereas in epileptic mice, P2X7R up-regulation occurred in microglia as well as in neurons. Pretreatment of mice with the specific P2X7R inhibitor A-438079 reduced electrographic and clinical seizure severity during status epilepticus and reduced seizure-induced neuronal death in the neocortex. SIGNIFICANCE: Our findings identify neurons in the neocortex as an important site of P2X7R up-regulation after status epilepticus and in epilepsy, and provide support for the possible use of P2X7R antagonists for the treatment of status epilepticus and prevention of seizure-induced brain damage.
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.[Pubmed:20387084]
J Neural Transm (Vienna). 2010 Jun;117(6):681-7.
The role of the ATP-gated receptor, P2X(7), has been evaluated in the unilateral 6-OHDA rat model of Parkinson's disease using the P2X(7) competitive antagonist A-438079. Nigral P2X(7) immunoreactivity was mainly located in microglia but also in astroglia. A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores. However, this was not associated with a reduction of DA cell loss. Blockade of P2X(7) receptors may represent a novel protective strategy for striatal DA terminals in Parkinson's disease and warrants further future investigation.
